ArticleThe Canadian journal of urology2025
Impact of metabolic syndrome on combination therapy efficacy in LUTS due to BPH: a prospective study.
Article in The Canadian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBenign prostatic hyperplasia (BPH) is a common benign tumor in men, with an age-related prevalence of multifactorial etiology. The present study aimed to accurately assess and predict the effect of co-existing metabolic syndrome (MtS) upon treatment outcomes of combination medical therapy in select patients of lower urinary tract symptoms (LUTS) due to BPH.
methodsAfter obtaining informed consent from the patients, 70 eligible patients with LUTS due to BPH with and without MtS were enrolled in this study from September 2022 to January 2024 from the outpatient clinic at the University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi and were treated with a combination of Tamsulosin and Dutasteride, for two months, as per the protocol. The outcomes measured were a change in the International Prostate Symptom Score (IPSS), mean flow rate (MFR), and peak urine flow (Qmax) rates. Data was analysed using SPSS version 23.
resultsThe reduction in IPSS was higher in the control group than in the case group (p < 0.001), and the difference in MFR between the groups was also statistically significant (p < 0.001). Although there was a significant change in Qmax in both groups, the difference in the improvement in Qmax between the two groups was not significant (p < 0.829). The control group appeared to have achieved better symptomatic relief after treatment than did the case group.
conclusionMetabolic syndrome had a negative adverse impact on medical treatment outcomes in selected patients of LUTS due to BPH. The study suggests that urologists should actively consider and appropriately counsel patients with LUTS-BPH and co-existing metabolic syndrome before selecting such patients for combination medical therapy.
Indexed as
Identifiers
40910327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.